Comparative Pharmacology
Head-to-head clinical analysis: BONCRESA versus FOSAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONCRESA versus FOSAMAX.
BONCRESA vs FOSAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BONCRESA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and readily excreted metabolite, thereby reducing serum uric acid levels.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
5 mg orally once daily, with or without food; maximum dose 10 mg once daily.
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14 h); clinically relevant for once-daily dosing
Terminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
Renal: 70% unchanged; fecal: 20% as metabolites; biliary: minor (<5%)
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Category C
Category C
Bisphosphonate
Bisphosphonate